Insider Selling: Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Sells $489,693.75 in Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 13,125 shares of Harmony Biosciences stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $37.31, for a total transaction of $489,693.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jeffrey Dierks also recently made the following trade(s):

• On Monday, January 27th, Jeffrey Dierks sold 1,629 shares of Harmony Biosciences stock. The shares were sold at an average price of $38.02, for a total value of $61,934.58.
• On Tuesday, January 21st, Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.00, for a total value of $44,920.00.
• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The stock was sold at an average price of $37.01, for a total transaction of $388,864.07.

Harmony Biosciences Stock Performance

HRMY opened at $39.54 on Friday. The firm’s 50-day moving average price is $35.20 and its 200-day moving average price is $35.22. The company has a market cap of $2.26 billion, a P/E ratio of 18.74, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 52-week low of $28.14 and a 52-week high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. During the same period in the previous year, the firm posted $0.63 earnings per share. The business’s revenue for the quarter was up 16.0% compared to the same quarter last year. As a group, equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Institutional Trading of Harmony Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HRMY. GAMMA Investing LLC raised its stake in shares of Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after purchasing an additional 436 shares during the last quarter. Mendota Financial Group LLC increased its holdings in Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after buying an additional 965 shares during the period. CWM LLC raised its position in Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after buying an additional 775 shares during the last quarter. Quarry LP acquired a new stake in Harmony Biosciences during the 2nd quarter valued at approximately $62,000. Finally, KBC Group NV boosted its holdings in shares of Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after acquiring an additional 819 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on HRMY. Oppenheimer reiterated an “outperform” rating and set a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Harmony Biosciences in a report on Monday. Needham & Company LLC restated a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a research note on Monday, January 13th. Mizuho lifted their target price on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday, October 10th. Finally, Raymond James reissued an “outperform” rating and set a $40.00 price target on shares of Harmony Biosciences in a research report on Thursday, October 10th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $55.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.